In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific.
AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available PTCA dilation catheter in patients with in-stent restenosis of a previously treated lesion, up to 26mm in length.
600 patients were enrolled in the trial, and were randomised 2:1 to receive either POBA or the AGENT DCB. Results showed that the AGENT DCB was superior to conventional balloon angioplasty in the primary endpoint of target lesion failure at one year (17.9% vs. 28.7%; P=0.006).
Interview Questions:
-What are the unmet needs of ISR patients?
-What are the unique features of the AGENT balloon?
-What was the patient population and study design?
-What were the key findings?
-What are your take-home messages?
-What further study is required?
Recorded remotely from Boston, 2023.
Visit Radcliffe Cardiology: www.radcliffecardiology.com/?...
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: / radcliffecardiology
Follow us on X: x.com/radcliffeCARDIO
Негізгі бет Ғылым және технология TCT 23: AGENT IDE: AGENT Paclitaxel Coated Balloon Angioplasty for In-Stent Restenosis
Пікірлер: 2